Adjuvant Therapy for Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 June 2024 | Viewed by 252
Special Issue Editor
Interests: cancer metabolism; signaling pathways; oncogenes; tumor suppressors; targeted therapies; genetic alterations; tumor microenvironment; biomarkers
Special Issue Information
Dear Colleagues,
Pancreatic cancer is one of the deadliest cancers with a dismal prognosis. Surgical resection combined with adjuvant chemotherapy is a common treatment option for resectable tumors. Multiple randomized clinical trials have shown that tumor resection followed by adjuvant chemotherapies enables the overall and progression-free survival of pancreatic cancer patients. However, the increased rate of metastases leads to ineffective therapies. So, there is an urgent need for better approaches to target this metastatic disease. Currently, ongoing research in pancreatic cancer is exploring personalized therapies including combined adjuvant options by evaluating novel therapeutic targets and the use of genetic and other biomarkers. In addition, there has been tremendous progress towards the advancement of adjuvant chemotherapy protocols, which are evidence-based, to extend long-term survival benefits.
So far, mFOLFIRINOX (modified fluorouracil/irinotecan/oxaliplatin regimen) is regarded as the most effective systemic treatment option as an adjuvant therapy for selected as well as healthy subjects. In contrast, gemcitabine or GEMCAP (gemcitabine plus capecitabine) therapies are suggested for elderly patients or those with ECOG PS 2 (Eastern Co-operative Oncology Group Performance Status 2). Another approach worth investigating would be the response of immune checkpoint inhibitors (ICIs) in rare MSI-H (high microsatellite instability) PDAC (pancreatic ductal adenocarcinoma) patients.
The currently employed radiological tests are ineffective for identifying micro-metastatic disease, which indicates the requirement of biomarkers for the early detection of metastatic features in PDAC patients. Furthermore, the effect of adjuvant radiation therapy leading to improved outcomes of PDAC patients is debatable, owing to the scarcity of data that can validate the techniques and dosage used for radiotherapy. This Special Issue will highlight the current treatment options in pancreatic cancer, the progress demonstrated by new strategies, future prospects for improving targeted therapies and effective neoadjuvant therapies that offer improved survival benefits to patients with this extremely complex and heterogeneous disease.
Dr. Sonam Kumari
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chemotherapy
- pancreatic resections
- overall survival
- gemcitabine
- pancreatic ductal adenocarcinoma
